Table 1. Baseline characteristics.

Number of cases	29
Age	63.7 ± 9.6
Male / Female	14 / 15
AST (U/L)	52.0 ± 28.7
ALT (U/L)	55.2 ± 31.7
Platelet (x10-9/L)	126 ± 56.3
Albumin (g/dl)	3.9 ± 0.37
AFP (ng/ml)	11.9 ± 29.0
Histological diagnosis (METAVIR score)
Activity score (0-1/ 2/ 3)	14/ 12/ 1
Fibrosis stage (0-1/ 2/ 3–4)	14/ 5/ 10
IL28B (rs8099917) (TT/ TG or GG)	28/ 1
Prior treatment (Naïve / Relapse / NR)	10/ 12/ 7
Treatment outcomes (SVR/ Relapse / NR)	25/ 0/ 4

AST, aspartate aminotransferase’

ALT, alanine aminotransferase’

AFP, alpha-fetoprotein’

PR therapy, pegylated interferon plus ribavirin therapy’

RAV, resistance-associated variants’

SMV/PR therapy; Simeprevir plus pegylated interferon / ribavirin therapy’

TVR, telaprevir,

SVR; sustained virological response